Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study - Gooderham, Melinda; Guttman-Yassky, Emma; Igawa, Ken; Kabashima, Kenji; Esfandiari, Ehsanollah; Rylands, Angela J.; Williams, Angela; Nixon, Annabel; Dent, Jennifer E.; Simpson, Eric (Dermatology and therapy, 2024)
Keywords: Adults; Atopic dermatitis; Biological products; Body mass index; Care and treatment; Clinical outcomes; Clinical trials; Demographics; Dermatitis; Dermatology; Dermatology Life Quality Index; Evaluation; Health-related quality of life (HRQL); Internal Medicine; Medical history; Medicine; Medicine & Public Health; Mental health; Methods; Missing data; Monoclonal antibodies; Oral and Maxillofacial Surgery; Original Research; Plastic Surgery; Pruritus; Quality of life; Quality of Life Research; Rocatinlimab; Skin diseases; Sleep; Sleep disturbance; Topical medication; Variance analysis; Canada; United States--US; Japan; Germany; Sleep disturbance; Pruritus; Atopic dermatitis; Dermatology Life Quality Index; Health-related quality of life (HRQL); Rocatinlimab